Welcome to our dedicated page for AGTC news (Ticker: AGTC), a resource for investors and traders seeking the latest updates and insights on AGTC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AGTC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AGTC's position in the market.
Applied Genetic Technologies Corporation (AGTC) announced positive findings from the ongoing Phase 1/2 trial of AGTC-501 for treating X-linked retinitis pigmentosa (XLRP). Data presented at the ARVO 2022 meeting show sustained safety and efficacy over 18 months, with two-thirds of patients recovering foveal ellipsoid zone (EZ) and nearly half reporting improved macular sensitivity. AGTC-501 demonstrated good tolerability, with mostly mild adverse events. The company is optimistic about AGTC-501's potential and plans to share more results from ongoing trials later in 2022.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) revealed promising preclinical data at the 25th Annual Meeting of the ASGCT, focusing on gene therapies for inherited retinal diseases and expanding to neurodegenerative diseases like frontotemporal dementia (FTD). The data showed sustainable expression of progranulin via AAV vectors in non-human primates, potentially addressing FTD caused by GRN mutations. The company's approaches also include a hybrid dual AAV strategy for Stargardt disease, showcasing advancements in AAV technology and paving the way for future clinical developments.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced that Sue Washer, President & CEO, will present at the Alliance for Regenerative Medicine Cell & Gene Meeting in Barcelona on April 21 at 9:30 PM CEST. AGTC focuses on AAV-based gene therapies for rare diseases, particularly inherited retinal diseases. The company is advancing clinical trials for X-linked retinitis pigmentosa and achromatopsia, alongside preclinical programs in optogenetics and CNS disorders. For more details, visit meetingonthemed.com.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced multiple presentations at the ARVO 2022 annual meeting concerning ongoing clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM). Key presentations include interim safety results and findings on visual photosensitivity from Phase 1/2 trials. With a focus on gene therapy for rare inherited retinal diseases, AGTC aims to validate its technology platform. Results from these studies may support future regulatory filings, emphasizing the potential impact of AGTC’s therapies on patient care.
Applied Genetic Technologies Corporation (AGTC) announced a public offering of 7,500,000 shares of its common stock, aiming for approximately $9.8 million in gross proceeds. The offering is slated to close on or around March 24, 2022, subject to customary conditions. AGTC intends to use the proceeds to support its ongoing clinical trials in the X-linked retinitis pigmentosa (XLRP) and Achromatopsia (ACHM) programs, as well as for general corporate purposes. Cantor Fitzgerald & Co. is the sole book-running manager for the offering.
Applied Genetic Technologies Corporation (AGTC) has launched an underwritten public offering of its common stock, with all shares being sold by the company. The offering includes a 30-day option for the underwriter to purchase an additional 15% of shares. Proceeds will support ongoing clinical trials in its X-linked retinitis pigmentosa (XLRP) and Achromatopsia (ACHM) programs and other corporate purposes. Cantor Fitzgerald & Co. is the sole book-running manager for the offering, which is subject to market conditions and cannot be guaranteed to complete.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced participation in several upcoming virtual investor conferences. Jon Lieber, CFO, will present at the 34th Annual ROTH Conference on March 13-15, 2022. Sue Washer, President and CEO, will be on a panel at the Cantor Fitzgerald Virtual Rare Orphan Disease Summit on March 29, 2022, discussing gene therapy for rare diseases. Additionally, a fireside chat with Ms. Washer will be held at the H.C. Wainwright Gene Therapy and Gene Editing Conference on March 30, 2022. Replays of the events will be available on the Company's website.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced its financial results for the quarter ending December 31, 2021, reporting a net loss of $19.1 million. The company is preparing to release interim results from the SKYLINE trial in Q2 2022 and expects to provide further updates on its X-linked retinitis pigmentosa (XLRP) and achromatopsia programs. AGTC has enrolled 14 patients in the SKYLINE trial, exceeding its target. The company is also progressing on its new manufacturing facility, aiming for initial operations in Q4 2022.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced positive interim results from its Phase 1/2 study of AGTC-401, a gene therapy for achromatopsia (ACHMB3). Data from pediatric patients showed a favorable safety profile and over 50% response rate in visual sensitivity improvements at the highest dose (1.1E+12 vg/mL). The totality of results supports its advancement, with no new serious adverse reactions observed. AGTC plans to consult with the FDA later this year for the next steps in clinical development.
